Assessment of response to treatment with the PI3K/mTOR inhibitor BEZ235 with FLT PET in a tumor xenograft model

被引：0
|
作者：
Wanek, T. [1 ]
Fuereder, T. [2 ]
Pflegerl, P. [2 ]
Jaeger-Lansky, A. [2 ]
Hoeflmayer, D. [2 ]
Strommer, S. [2 ]
Mueller, M. [2 ]
Langer, O. [1 ]
Kuntner, C. [1 ]
Wacheck, V. [2 ]
机构：
[1] Austrian Inst Technol, Seibersdorf, Austria
[2] Med Univ Vienna, Vienna, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2010年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S298 / S299
页数：2
相关论文
共 50 条
  • [41] PI3K Inhibitors for Cancer Treatment: Five Years of Preclinical and Clinical Research after BEZ235
    Maira, Sauveur-Michel
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2016 - 2016
  • [42] NVP-BEZ235, A Dual PI3K/mTOR Inhibitor, Enhances Chemotherapy and Antiangiogenic Response in Pancreatic Cancer
    Ostapoff, K. T.
    Awasthi, N.
    Yen, P. L.
    Zhang, C.
    Schwarz, M. A.
    Brekken, R. A.
    Schwarz, R. A.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S46 - S46
  • [43] The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
    Bhende, P. M.
    Park, S. I.
    Lim, M. S.
    Dittmer, D. P.
    Damania, B.
    LEUKEMIA, 2010, 24 (10) : 1781 - 1784
  • [44] The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
    P M Bhende
    S I Park
    M S Lim
    D P Dittmer
    B Damania
    Leukemia, 2010, 24 : 1781 - 1784
  • [45] Radiation Sensitization of Head and Neck Tumor Cells using the dual PI3K/mTOR Inhibitor NVP-BEZ235
    Balzer, V.
    Subtil, F.
    Dikomey, E.
    Engenhart-Cabillic, R.
    Schoetz, U.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S233 - S233
  • [46] Preclinical efficacy of the novel dual PI3K/mTOR inhibitor, BEZ235 compared with RAD001 in HER2+breast tumors
    De, Pradip K. R.
    Sun, Yuliang
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2011, 71
  • [47] Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
    Hall, Connor P.
    Reynolds, C. Patrick
    Kang, Min H.
    CLINICAL CANCER RESEARCH, 2016, 22 (03) : 621 - 632
  • [48] NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Serra, Violeta
    Markman, Ben
    Scaltriti, Maurizio
    Eichhorn, Pieter J. A.
    Valero, Vanesa
    Guzman, Marta
    Luisa Botero, Maria
    Llonch, Elisabeth
    Atzori, Francesco
    Di Cosimo, Serena
    Maira, Michel
    Garcia-Echeverria, Carlos
    Lluis Parra, Josep
    Arribas, Joaquin
    Baselga, Jose
    CANCER RESEARCH, 2008, 68 (19) : 8022 - 8030
  • [49] Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models
    Uestuen, Sevdican
    Lassnig, Caroline
    Preitschopf, Andrea
    Mikula, Mario
    Mueller, Mathias
    Hengstschlaeger, Markus
    Weichhart, Thomas
    TRANSPLANT IMMUNOLOGY, 2015, 33 (01) : 45 - 50
  • [50] Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
    Zou, Hong
    Li, Li
    Carcedo, Ines Garcia
    Xu, Zhi Ping
    Monteiro, Michael
    Gu, Wenyi
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2016, 11 : 1947 - 1958
12345